Literature DB >> 27582850

Pheochromocytoma in pregnancy: a case report and review of literature.

J George1, J Y L Tan1.   

Abstract

Hypertension is a common problem in pregnancy that can result in significant maternal and fetal morbidity and mortality. The common causes include pre-eclampsia, gestational hypertension and essential hypertension. Although phaeochromocytoma is a rare cause of hypertension in pregnancy, it can lead to potentially life-threatening cardiovascular complications for the mother and increased fetal mortality if left undiagnosed and untreated. The diagnosis can be confirmed by measurement of plasma and urinary catecholamines and their metabolities followed by radiological localization of the tumour. Surgical resection of the tumour after adequate pre-operative control of hypertension using sequential alpha- followed by beta-blockers is the definitive treatment. In pregnancy, depending on the gestation at which diagnosis is made, the optimal timing for surgery is during the late first or early second trimester. When the pregnancy is more advanced, medical management followed by combined caesarean section and tumour resection closer to term is preferred.

Entities:  

Keywords:  hypertension; phaeochromocytoma; pregnancy

Year:  2010        PMID: 27582850      PMCID: PMC4989691          DOI: 10.1258/om.2010.090063

Source DB:  PubMed          Journal:  Obstet Med        ISSN: 1753-495X


  19 in total

1.  Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes.

Authors:  C Bauters; M-C Vantyghem; E Leteurtre; M-F Odou; C Mouton; N Porchet; J-L Wemeau; C Proye; P Pigny
Journal:  J Med Genet       Date:  2003-06       Impact factor: 6.318

2.  Neonatal effects of long-term maternal phenoxybenzamine therapy.

Authors:  Stephanie C Aplin; Kevin F Yee; Michael J Cole
Journal:  Anesthesiology       Date:  2004-06       Impact factor: 7.892

Review 3.  Adrenal disorders in pregnancy.

Authors:  John R Lindsay; Lynnette K Nieman
Journal:  Endocrinol Metab Clin North Am       Date:  2006-03       Impact factor: 4.741

4.  Biochemical diagnosis of pheochromocytoma: which test is best?

Authors:  Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

5.  Pheochromocytoma and pregnancy. Review of 89 cases.

Authors:  J G Schenker; I Chowers
Journal:  Obstet Gynecol Surv       Date:  1971-11       Impact factor: 2.347

6.  Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.

Authors:  P F Plouin; G Chatellier; I Fofol; P Corvol
Journal:  Hypertension       Date:  1997-05       Impact factor: 10.190

7.  Pheochromocytoma in pregnancy. Experience of treatment with phenoxybenzamine in three patients.

Authors:  G Stenström; K Swolin
Journal:  Acta Obstet Gynecol Scand       Date:  1985       Impact factor: 3.636

8.  Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan.

Authors:  Masao Omura; Jun Saito; Kunio Yamaguchi; Yukio Kakuta; Tetsuo Nishikawa
Journal:  Hypertens Res       Date:  2004-03       Impact factor: 3.872

9.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

10.  Secondary hypertension in a blood pressure clinic.

Authors:  A M Sinclair; C G Isles; I Brown; H Cameron; G D Murray; J W Robertson
Journal:  Arch Intern Med       Date:  1987-07
View more
  1 in total

1.  Laparoscopic approach to pheochromocytoma in pregnancy: case report.

Authors:  Felipe de Almeida E Paula; Ravisio Israel Dos Santos; Odivaldo Antonio Ferruzzi; Rafael Osti Melo; Mariana Takaku
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.